Dr. Pourdehnad is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
400 Parnassus Ave
San Francisco, CA 94143Phone+1 415-353-2252Fax+1 415-353-2765
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2009 - 2012
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2005 - 2009
Chicago Medical School at Rosalind Franklin University of Medicine and ScienceClass of 2005
Certifications & Licensure
CA State Medical License 2009 - 2026
NY State Medical License 2007 - 2009
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
Clinical Trials
- Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma Start of enrollment: 2013 Dec 18
- A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia Start of enrollment: 2020 Aug 05
Publications & Presentations
PubMed
- 1 citationsModel based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC-92480), a novel cereblon E3 ligase modulator.Fan Wu, Liangang Liu, Allison Gaudy, Xiaomin Wang, Leon Carayannopoulos
CPT. 2023-10-01 - 8 citationsPhase Ib study of avadomide (CC-122) in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma.Loretta J Nastoupil, John Kuruvilla, Julio C Chavez, Fontanet Bijou, Thomas E Witzig
Ejhaem. 2022-05-01 - 5 citationsPhase Ib study of combinations of avadomide (CC-122), CC-223, CC-292, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.Vincent Ribrag, Julio C Chavez, Carola Boccomini, Jason Kaplan, Jason C Chandler
Ejhaem. 2022-02-01
Abstracts/Posters
- A Novel Cereblon E3 Ligase Modulator Eradicates Acute Myeloid Leukemia Stem Cells through Degradation of Translation Termination Factor GSPT1Michael Pourdehnad, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- Career-Development Lunch Sessions: Industry Careers60th American Society of Hematology Annual Meeting - 12/1/2018
- Avadomide (CC-), a Novel Cereblon Modulating Agent, Plus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016
Deadliest Cancers May Respond to New Drug Treatment StrategyJanuary 29th, 2016
Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient NeedsDecember 13th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
